Diana J Leeming
Overview
Explore the profile of Diana J Leeming including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
2275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansen A, Lorentzen L, Leeming D, Sand J, Hagglund P, Davies M
Anal Biochem
. 2025 Mar;
702:115837.
PMID: 40058539
The precision-cut lung slice (PCLS) model is an ex vivo tissue system that has been used to model disease and examine the effects of exogenous compounds. Few studies have been...
2.
Dekkers B, Kerstjens H, Breisnes H, Leeming D, Anthony R, Frijlink H, et al.
J Infect Dis
. 2025 Feb;
PMID: 39932906
Background: Adjunctive host-directed therapies are investigated that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis (TB). Macrolides, including azithromycin, were shown to possess anti-inflammatory...
3.
Pillay J, Flikweert A, van Meurs M, Grootenboers M, van der Sar-van der Brugge S, van der Voort P, et al.
Respir Res
. 2025 Jan;
26(1):32.
PMID: 39844140
Background: Severe and critical COVID-19 is characterized by pulmonary viral infection with SARS-CoV-2 resulting in local and systemic inflammation. Dexamethasone (DEX) has been shown to improve outcomes in critically ill...
4.
Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767
Ramachandran P, Brice M, Sutherland E, Hoy A, Papachristoforou E, Jia L, et al.
Hepatol Commun
. 2024 Nov;
8(12).
PMID: 39585303
Background: The farnesoid X receptor (FXR) is a leading therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH)-related fibrosis. INT-767, a potent FXR agonist, has shown promise in preclinical models. We aimed...
5.
Schmidt-Christensen A, Eriksson G, Laprade W, Pirzamanbein B, Hornberg M, Linde K, et al.
Sci Rep
. 2024 Oct;
14(1):23014.
PMID: 39362932
Metabolic dysfunction-associated steatohepatitis (MASH) is a common but frequently unrecognized complication of obesity and type 2 diabetes. The association between these conditions is multifaceted and involves complex interactions between metabolic,...
6.
Laursen T, Kjaer M, Leeming D, Gronbaek H
Liver Int
. 2024 Aug;
44(11):3108-3109.
PMID: 39206769
No abstract available.
7.
Fainberg H, Moodley Y, Triguero I, Corte T, Sand J, Leeming D, et al.
Lancet Respir Med
. 2024 Jul;
12(9):681-692.
PMID: 39025091
Background: Pulmonary fibrosis results from alveolar injury, leading to extracellular matrix remodelling and impaired lung function. This study aimed to classify patients with pulmonary fibrosis according to blood biomarkers to...
8.
Thorburn D, Leeming D, Barchuk W, Wang Y, Lu X, Malkov V, et al.
Hepatol Commun
. 2024 Jul;
8(7).
PMID: 38967589
Background: Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage...
9.
Karsdal M, Hallsworth K, Scragg J, Leeming D, Villesen I, Avery L, et al.
Hepatol Commun
. 2023 Sep;
7(10).
PMID: 37756043
Background: NAFLD is associated with activation of fibroblasts and hepatic fibrosis. Substantial patient heterogeneity exists, so it remains challenging to risk-stratify patients. We hypothesized that the amount of fibroblast activity,...
10.
Lonsmann I, Grove J, Haider A, Kaye P, Karsdal M, Leeming D, et al.
Biology (Basel)
. 2023 Aug;
12(8).
PMID: 37626973
Background: Identification of progressive liver disease necessitates the finding of novel non-invasive methods to identify and monitor patients in need of early intervention. Investigating patients with early-liver injury may help...